Bibliografía

1. Moreno RP, Metnitz PGH, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005;31:1345–55.
2. Zimmerman JE, Kramer AA, McNair DS, Malila FN. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med. 2006;34:1297–310.
3. Rubio O, Arnau A, Cano S, Subirà C, Balerdi B, Perea ME, et al. Limitation of life support techniques at admission to the intensive care unit: a multicenter prospective cohort study. J Intensive Care. 2018;6:24.
4. Sinuff T, Adhikari NK, Cook DJ, Schünemann HJ, Griffith LE, Rocker G, et al. Mortality predictions in the intensive care unit: comparing physicians with scoring systems. Crit Care Med. 2006;34:878–85.

Rafael Fernandez*, Lara Ventura, Caroline Macharete, Ignacio Catalan, Silvia Cano, Josep-Maria Alcoverro, Carles Subira, Jaume Masclans, Gina Rognoni, Olga Rubio

Critical Care Department, Althaia Xarxa Assistencial Universitaria de Manresa, CIBERES, Universitat Internacional de Catalunya, Spain

* Corresponding author.
E-mail address: rfernandezf@althaia.cat (R. Fernandez).

Lymphopenic hospital acquired sepsis (L-HAS): An immunological phenotype conferring higher risk of mortality☆

Sepsis nosocomial linfopénica: un fenotipo inmunológico que confiere un mayor riesgo de mortalidad

The clinical profile of Hospital Acquired Sepsis (HAS) is poorly known. In a recent work,[1] we found that patients suffering from HAS show many of the risk factors associated with cardiovascular disease and cancer.

Lymphopenia is a frequent finding in sepsis patients.[2–4] Sepsis affects the immune system by directly altering the lifespan, production and function of the effector cells responsible for homeostasis.[5] Lymphopenia is also found in other severe infections like pneumonia needing of hospitalization, and it is associated to an increased risk of mortality.[6]

The impact of lymphocyte counts on the prognosis of patients with HAS is unknown. The objective of the present study was to evaluate the association between lymphocyte counts and mortality risk of the patients suffering from HAS. The predictive ability of the other leukocyte subpopulations was also assessed.

The study was approved by the Clinical Research and Ethics Committee of our hospital. Informed consent was waived due to the observational nature of the study.

A total of 196 patients were included in the study. Hospital and 90 days mortality was 45.4%. The median age of HAS patients was of 73 years (IQR: 68.1–71.4), with 68.4% ($n = 134$) of them being male. Some serious comorbidities were: cardiac disease 63.8% ($n = 125$), cancer 34.2% ($n = 67$), chronic kidney disease 19.4% ($n = 38$), immunosuppression 17.9% ($n = 35$) and chronic hepatic disease 6.1% ($n = 12$) (Supplementary Table 1). Sepsis with organ failure (severe sepsis/septic shock) was present in 146 patients (74.5%) with 75 of these patients dying during the first 90 days.

HAS emerged 10 days following hospital admission in median (IQR, 11.4–14.5). The most frequent source of infection was the respiratory tract (29.1%), followed by bacteraemia (25%) (Supplementary Table 1). Microorganisms were isolated in one hundred and fifty patients (76.5%). Gram negative bacteria were the most common microorganisms (58.6%), followed by Gram positive cocci (46.0%).

We collected leukocyte subpopulations counts at hospital admission and also at HAS diagnosis. Patients with HAS showed a significant increase in the median values of neutrophil counts from admission to diagnosis: (5.3 [4.00–7.4] $\times 10^3/\text{mm}^3$) *vs* (10.9 [6.5–17.0] $\times 10^3/\text{mm}^3$) $p < 0.001$. On the contrary, median values of eosinophil and lymphocyte counts decreased from admission to diagnosis: (0.11 [0.04–0.22] $\times 10^3/\text{mm}^3$) *vs* (0.02 [0.00–0.11] $\times 10^3/\text{mm}^3$) for eosinophils and (1.6 [1.0–2.3] $\times 0^3/\text{mm}^3$) *vs* (0.8 [0.4–1.3] $\times 10^3/\text{mm}^3$]) for lymphocytes (with differences yielding a $p < 0.001$ in both cases). Median values of monocytes and basophil counts did not change in a significant manner between both moments.

Median values of lymphocytes at HAS diagnosis were higher in survivors than in non survivors. Survivors showed also higher median values of eosinophils at HAS diagnosis than non survivors. On the contrary, monocyte, basophil and neutrophil counts did not show differences between both groups (Supplementary Table 1).

Lymphocytes and eosinophil counts at HAS diagnosis showed significant AUCs for identifying survivors at hospital discharge (Supplementary Fig. 1), with an (AUC [CI95%], p) of (0.59 [0.59–0.67], 0.042) and (0.60 [0.52–0.68], 0.023) respectively. Other leukocyte subtypes failed to discriminate survivors from non survivors. The optimal operating point (OOP) was calculated for those leukocyte subpopulations showing an AUC $p < 0.05$ as previously described[7] for distinguishing between both kinds of patients in the AUC analysis was 775 cells/mm³ for lymphocytes and 13 cells/mm³ for eosinophils.

Table 1 Multivariate regression analysis to predict hospital mortality risk in patients with ≤775 lymphocytes/mm^3 at diagnosis of HAS.

Variables	Hospital mortality		
	OR	(95% CI)	p
Age (years)	1.034	[1.002–1.067]	0.040
Sex (male)	2.067	[0.978–4.369]	0.057
''Sepsis Code'' implemented	0.583	[0.294–1.157]	0.123
Vascular disease	1.419	[0.650–3.096]	0.380
Cancer	1.385	[0.680–2.818]	0.369
Chronic kidney disease	1.693	[0.713–4.021]	0.233
Sepsis with organ failure	4.687	[1.889–11.629]	0.001
More than one episode of sepsis during hospital admission	3.346	[1.529–7.324]	0.003
Time (days) from admission to sepsis diagnosis	1.036	[1.000–1.074]	0.050
Surgical intervention	0.316	[0.144–0.696]	0.004
≤775 lymphocytes/mm^3	1.983	[1.004–3.919]	0.049

OR: odds ratio; CI: confidence interval.

Categorical variables were created based on the OOPs and the resulting variables for lymphocyte and eosinophil counts were evaluated for hospital mortality prediction using multivariate analysis adjusting by the potential confounding factors selected in the univariate analysis: [Age(years)], [Sex(male)], [''Sepsis code'' implemented], [antecedent of vascular disease], [antecedent of cancer], [antecedent of chronic kidney disease], [sepsis with organ failure], [more than one episode of sepsis during hospital admission], [surgical intervention] and [time (days) from admission to sepsis diagnosis]. The presence of a lymphocyte count ≤775 cells/mm^3 at diagnosis of HAS was an independent predictor of mortality in the multivariate analysis: (1.98 [1.00–3.92], $p=0.049$) (OR 1.98 [CI 95% 1.00–3.92], $p = 0.049$) (Table 1). In turn, showing a eosinophil count ≤13 cells/mm^3 at diagnosis of HAS conferred a non-significant higher risk of mortality (1.87 [0.95–3.70], $p=0.072$). Finally, the Kaplan–Meier curves at 90 days following diagnosis of HAS showed that patients with ≤775 lymphocytes/mm^3 died earlier (media 48.6 days [40.3–56.8]) than patients with >775 lymphocytes/mm^3 (media 60.5 [53.1–67.9]), $p=0.030$ (Fig. 1).

HAS was characterized by a significant increase in the blood counts of the paradigmatic cell representing innate immunity, the neutrophil, accompanied by a decrease in the prototypic cell of the adaptive immunity, the lymphocyte. Neutrophil count expansion could represent a kind of compensatory mechanism responding to the decrease in the lymphocyte counts, which precedes the emergence of HAS. The significant decrease in lymphocyte counts found from admission to diagnosis of HAS cannot be explained by hemodilution due to fluid administration, since counts of the other leukocyte subsets were not affected. In consequence, this is the first report providing evidence that sepsis does induce diminution of lymphocyte counts in blood.

Early identification of patients at risk of death is a crucial step in the clinical management of sepsis.[8–10] In this regard, this study provides a cut-off value for lymphocyte counts (≤775 cells/mm^3) which is useful for the early identification of those patients at higher risk of mortality, independently of

their accompanying co-morbidities (Table 1) (Fig. 1). Also we repeat analysis excluding immunosuppressed patients and we found that those patients with ≤775 lymphocytes/mm^3 continue presenting higher risk to mortality.

Lymphocyte counting is a simple and inexpensive test, widely available in most hospital settings. In our study, the eosinophil count at diagnosis of HAS conferred a nonsignificant higher risk of mortality. Some limitations of our work were its retrospective nature, the absence of some variables like the albumin levels or severity scores like SOFA or APACHE.

In conclusion, lymphopenic HAS (L-HAS) (≤775 lymphocytes/mm^3) constitutes a particular immunological phenotype of the disease conferring a two-fold increase in the risk of hospital mortality. Patients with

Figure 1 Kaplan–Meier survival curve. Groups were compared by the log rank test (Mantel–Henzel). Circulating Lymphocyte Count (CLC) at HAS diagnosis were divided in two groups, ≤775 lymphocytes/mm^3 and greater. Time was censored at 90 days following HAS diagnosis. Cum: cumulative.

L-HAS deserve special care and close monitoring of vital signs.

Conflict of interest

None.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.medin. 2018.09.015

Bibliografía

1. López-Mestanza C, Andaluz-Ojeda D, Gómez-López JR, Bermejo-Martín JF. Clinical factors influencing mortality risk in hospital-acquired sepsis. J Hosp Infect. 2018;98:194–201.
2. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306:2594–605.
3. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock Augusta Ga. 2014;42:383–91.
4. Chung K-P, Chang H-T, Lo S-C, Chang L-Y, Lin S-Y, Cheng A, et al. Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsis. Shock Augusta Ga. 2015;43:569–75.
5. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126:23–31.
6. Bermejo-Martin JF, Cilloniz C, Mendez R, Almansa R, Gabarrus A, Ceccato A, et al. Lymphopenic community acquired pneumonia (L-CAP), an immunological phenotype associated with higher risk of mortality. EBioMedicine. 2017;24:231–6.
7. Almansa R, Ortega A, Ávila-Alonso A, Heredia-Rodríguez M, Martín S, Benavides D, et al. Quantification of immune dysregulation by next-generation polymerase chain reaction to improve sepsis diagnosis in surgical patients. Ann Surg. 2017.
8. Leon Gil C, Garcia-Castrillo Riesgo L, Moya Mir M, Artigas Raventos A, Borges Sa M, Candel González FJ, et al. Consensus document (SEMES-SEMICYUC) recommendations for the initial and multidisciplinary diagnostic management of severe sepsis in the hospital emergency departments. Med Intensiva. 2007;31:375–87.
9. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–53.
10. Jones SL, Ashton CM, Kiehne L, Gigliotti E, Bell-Gordon C, Disbot M, et al. Reductions in sepsis mortality and costs after design and implementation of a nurse-based early recognition and response program. Jt Comm J Qual Patient Saf Jt Comm Resour. 2015;41:483–91.

C. López-Mestanza[a,*], D. Andaluz-Ojeda[b],
J.R. Gómez-López[c], J.F. Bermejo-Martín[a]

[a] *BIO SEPSIS (Group of Biomedical Research in Sepsis), Hospital Clínico Universitario de Valladolid, SACYL, Valladolid, Spain*
[b] *Critical Care Medicine Service, Hospital Clínico Universitario de Valladolid, Valladolid, Spain*
[c] *General Surgery Service, Hospital de Medina del Campo, SACYL, Medina del Campo-Valladolid, Spain*

[*] Corresponding author.
E-mail address: xtina.lopez.mestanza@hotmail.com
(C. López-Mestanza).